Activity of the non-steroidal anti-inflammatory drug indomethacin against colorectal cancer

Cancer Treatment Reviews

Volumn 29, Issue 4, 2003, Pages 309-320

  Hull, M A ^a   Gardner, S H ^a   Hawcroft, G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Colorectal cancer; Cyclooxygenase; Indomethacin; Non steroidal anti inflammatory drug

Indexed keywords

ACETYLSALICYLIC ACID; BLEOMYCIN; CISPLATIN; DOXORUBICIN; EFLORNITHINE; FLUOROURACIL; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SULINDAC; SULINDAC SULFONE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; RAT; REVIEW; VERTIGO;

EID: 0041409648     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(03)00014-8     Document Type: Article

References (123)

1. Waddell WR, Gerner RE. Indomethacin and ascorbate inhibit desmoid tumors. J Surg Oncol 1980; 15: 85-90.
2. Waddell WR, Gerner RE, Reich MP. Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach. J Surg Oncol 1983; 22: 197-211.
3. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-87.
4. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316.
5. Nugent KP, Farmer KCR, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-1619.
6. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346: 1054-1059.
7. Hirata K, Itoh H, Ohsato K. Regression of rectal polyps by indomethacin suppository in familial adenomatous polyposis. Dis Colon Rectum 1994; 37: 943-946.
8. Lundholm K, Gelin J, Hyltander A, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602-5606.
9. Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981; 107: 658-663.
10. Al-Saleem T, Sabri Ali Z, Qassab M. Skin cancers in xeroderma pigmentosum: response to indomethacin and steroids. Lancet 1980; ii: 264-265.
11. Mertens WC, Bramwell VHC, Gwadry-Sridhar F, et al. Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2. Lancet 1992; 340:397-398.
12. Yoshinaga K, Teramura M, Iwabe K, et al. Anti-lymphoma effect of naproxen and indomethacin in a patient with relapsed diffuse large B-cell lymphoma. Am J Haematol 2001; 66: 220-223.
13. Kalgutkar AS, Marnett AB, Crews BC, et al. Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 2000; 43: 2860-2870.
14. Kalgutkar AS, Crews BC, Rowlinson SW, et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 2000; 97: 925-930.
15. Takeuchi K, Mizoguchi H, Araki H, et al. Lack of gastric toxicity of nitric oxide-releasing indomethacin, NCX-530, in experimental animals. Dig Dis Sci 2001; 46: 1805-1818.
16. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology 2001; 12: 88-93.
17. Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992-1998.
18. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-2072.
19. Winter CA, Risley EA, Nuss GW. Anti-inflammatory and antipyretic activities of indomethacin, 1-(p-chlorobenzoyl)-5- methoxy-2-methyl-indole-3-acetic acid. J Pharmacol Exp Ther 1963; 141: 369-371.
20. Shen T-Y, Winter CA. Chemical and biological studies on indomethacin, sulindac and their analogs. Adv Drug Res 1977; 12: 89-245.
21. Rhymer AR, Gengos DC. Indomethacin. In: Huskisson EC (ed.), Anti-rheumatic drugs. Praeger Publishers: New York, 1983; 265-278.
22. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231: 232-235.
23. Mercadante S. The use of anti-inflammatory drugs in cancer pain. Cancer Treat Rev 2001; 27: 51-61.
24. Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980; 64: 1323-1327.
25. Narisawa T, Satoh M, Sano M, Takahashi T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 1983; 10: 1225-1227.
26. Hirota C, Lida M, Aoyagi K, et al. Effect of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis. Cancer 1996; 78: 1660-1665.
27. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000; 11: 376-381.
28. Tanaka Y, Tanaka T, Ishitsuka H. Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants. Cancer Res 1989; 49: 5935-5939.
29. Golab J, Kozar K, Kaminski R, et al. Interleukin 12 and indomethacin exert a synergistic angiogenesis-dependent antitumor activity in mice. Life Sci 2000; 66: 1223-1230.
30. Min/+ mice. Prostaglandins Leukot Esssent Fatty Acids 2000; 62: 269-275.
31. Brown WA, Skinner SA, Malcontenti-Wilson C, et al. Nonsteroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. J Gastroenterol Hepatol 2000; 15: 1386-1392.
32. Charalambous DC, Farmer C, O'Brien PE. Sulindac and indomethacin inhibit formation of aberrant crypt foci in the colons of dimethylhydrazine treated rats. J Gastroenterol Hepatol 1996; 11: 88-92.
33. Barnes CJ, Hardman WE, Cameron IL, Lee M. Aspirin, but not sodium salicylate, indomethacin, or nabume-tone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats. Dig Dis Sci 1997; 42: 920-926.
34. Brown WA, Skinner SA, Malcontenti-Wilson C, et al. Nonsteroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 2001; 48: 660-666.
35. Narisawa T, Sato M, Sano M, et al. Prevention of colon polyposis and carcinomas by right hemicolectomy and indomethacin in animal model. Cancer 1985; 56: 1719-1724.
36. Siemer S, Kriener S, Konig J, et al. Influence of indomethacin and difluoromethylornithine on human tumour growth in nude mice. Eur J Cancer 1995; 31A: 976-981.
37. Rubio CA. Antitumoral activity of indomethacin on experimental esophageal tumors. J Natl Cancer Inst 1984; 72: 705-707.
38. Rubio CA. Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer 1986; 58: 1029-1031.
39. Lynch NR, Castes M, Astoin M, Salomon J-C. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer 1978; 38: 503-512.
40. Lynch NR, Salomon J-C. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst 1979; 62: 117-121.
41. Hial V, Horakova Z, Shaff RE, Beaven MA. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur J Pharmacol 1976; 37: 367-376.
42. Lonnroth C, Andersson M, Lundholm K. Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 2001; 18: 929-937.
43. Barnes CJ, Cameron IL, Hardman WE, Lee M. Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer 1998; 77: 573-580.
44. Hixson LJ, Alberts DS, Krutzsch M, et al. Anti-proliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994; 3: 433-438.
45. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179-188.
46. Hara A, Yoshimi N, Niwa M, et al. Apoptosis induced by NS398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997; 88: 600-604.
47. Smith M-L, Hawcroft G, Hull MA. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000; 36: 664-674.
48. Murphy VJ, Yang Z, Rorison KA, Baldwin GS. Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines. Cancer Lett 1998; 122: 25-30.
49. Hong SP, Ha SH, Park IS, Kim WH. Induction of apoptosis in colon cancer cells by nonsteroidal anti-inflammatory drugs. Yonsei Med J 1998; 39: 287-295.
50. Huang Y, Horvath CM, Waxman S. Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon γ, indomethacin and phenylbutyrate. Cancer Res 2000; 60: 3200-3206.
51. Turchanowa L, Dauletbaev N, Milovic V, Stein J. Nonsteroidal anti-inflammatory drugs stimulate spermidine/spermine acetyltransferase and deplete polyamine content in colon cancer cells. Eur J Clin Invest 2001; 31: 887-893.
52. Kralj M, Kapitanovic S, Kovacevic D, et al. Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells. J Cancer Res Clin Oncol 2001; 127: 173-179.
53. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95: 681-686.
54. Zhang L, Yu J, Ho Park B, et al. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290: 989-992.
55. Kim TI, Jin SH, Kim WH, et al. Prolonged activation of mitogen-activated protein kinases during NSAID-induced apoptosis in HT-29 colon cancer cells. Int J Colorectal Dis 2001; 16: 167-173.
56. His LC, Baek SJ, Eling TE. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res 2000; 256: 563-570.
57. 2+ mobilization and cAMP in HT-29 human colon adenocarcinoma cells. Cancer Lett 2000; 152: 217-222.
58. Gaffen JD, Chambers EA, Bennett A. The effects of dipyridamole and indomethacin on methotrexate cytotoxicity in LoVo human colon cancer cells. J Pharm Pharmacol 1989; 41: 350-352.
59. Tsuji S, Kawano S, Sawoaka H, et al. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 179-183.
60. Kokoska ER, Smith GS, Wolff AB, et al. Nonsteroidal antiinflammatory drugs attenuate epidermal growth factor-induced proliferation independent of prostaglandin synthesis inhibition. J Surg Res 1999; 84: 186-192.
61. Shiff SJ, Qiao L, Tsai L-L, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491-503.
62. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-245.
63. Qiao L, Hanif R, Sphicas E, et al. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem Pharmacol 1998; 55: 53-64.
64. Erickson BA, Longo WE, Panesar N, et al. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 1999; 81: 101-107.
65. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase 1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-7568.
66. Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999; 38: 779-788.
67. Gierse JK, Koboldt CM, Walker MC, et al. Kinetic basis for selective inhibition of cyclooxygenases. Biochem J 1999; 339: 607-614.
68. Kirtikara K, Swangkul S, Ballou LR. The analysis of nonsteroidal antiinflammatory drug selectivity in prostaglandin G/H synthase (PGHS)-null cells. Inflamm Res 2001; 50: 327-332.
69. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Cancer Rev 2001; 1: 11-21.
70. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999; 190: 445-450.
71. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 4705-4708.
72. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276: 18075-18081.
73. Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med 1999; 190: 451-459.
74. Chapple KS, Cartwright EJ, Hawcroft G, et al. Localisation of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156: 545-553.
75. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-1594.
76. Δ716 knockout mice. Nat Med 2001; 7: 1048-1051.
77. Ko SCW, Chapple KS, Hawcroft G, et al. Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene 2002; 21: 7175-7186.
78. Lehmann JM, Lenhard JM, Oliver BB, et al. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997; 272: 3406-3410.
79. Yamazaki R, Kusunoki N, Matsuzaki T, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor γ in rheumatoid synovial cells. J Pharmacol Exp Ther 2002; 302: 18-25.
80. 2 synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001; 62: 1587-1595.
81. Adamson DJ, Frew D, Tatoud R, et al. Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling. Mol Pharmacol 2002; 61: 7-12.
82. Brockman JA, Gupta RA, DuBois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115: 1049-1055.
83. Shimada T, Kojima K, Yoshiura K, et al. Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-664.
84. Gupta RA, DuBois RN. Controversy: PPARγ as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2002; 283: G266-G269.
85. Bienz M, Clevers H. Linking colorectal cancer to Wnt signalling. Cell 2000; 103: 311-320.
86. Wong NA, Pignatelli M. β-catenin - a linchpin in colorectal carcinogenesis? Am J Pathol 2002; 160: 389-401.
87. Brabletz T, Jung A, Reu S, et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001; 98: 10356-10361.
88. Hawcroft G, D'Amico M, Albanese C, et al. Indomethacin induces differential expression of β-catenin, γ-catenin and T-cell factor target genes in human colorectal cancer cells. Carcinogenesis 2002; 23: 107-114.
89. Brown WA, Skinner SA, Vogiagis D, O'Brien PE. Inhibition of β-catenin translocation in rodent colorectal tumors. A novel explanation for the protective effect of nonsteroidal antiinflammatory drugs in colorectal cancer. Dig Dis Sci 2001; 46: 2314-2321.
90. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation and attenuated β-catenin. Cancer Res 2000; 60: 3338-3342.
91. McEntee MF, Chiu C-H, Whelan J. Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 1999; 20: 635-640.
92. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57: 2909-2915.
93. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate β-catenin/TCF-4 signaling. Oncogene 2001; 20: 645-653.
94. Kolligs FT, Kolligs B, Hajra KM, et al. γ-Catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev 2000; 14: 1319-1331.
95. 2. J Biol Chem 2002; 277: 2614-2619.
96. Philipp A, Schneider A, Vasrik I, et al. Repression of cyclin D1: a novel function of MYC. Mol Cell Biol 1994; 14: 4032-4043.
97. Mitchell KO, Stacey Ricci M, Miyashita T, et al. Bax is a transcriptional target and mediator of c-Myc-induced apoptosis. Cancer Res 2000; 60: 6318-6325.
98. Giardina C, Sait Inan M. Nonsteroidal anti-inflammatory drugs, short-chain fatty acids, and reactive oxygen metabolism in human colorectal cancer cells. Biochim Biophys Acta 1998; 1401: 277-288.
99. Kang H-J, Song M-J, Choung SY, et al. Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. Biol Pharm Bull 2000; 23: 815-819.
100. Baek SJ, Kim K-S, Nixon JB, et al. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has pro-apoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 901-908.
101. Kim K-S, Baek SJ, Flake GP, et al. Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology 2002; 122: 1388-1398.
102. Baek SJ, Wilson LC, Lee C-H, Eling TE. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301: 1126-1131.
103. Kantor HS, Hampton M. Indomethacin in submicromolar concentrations inhibits cyclic AMP-dependent protein kinase. Nature 1978; 276: 841-842.
104. Zhu GH, Wong BCY, Eggo MC, et al. Non-steroidal antiinflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc. Br J Cancer 1999; 79: 393-400.
105. Zhu GH, Wong BCY, Slosberg ED, et al. Overexpression of protein kinase C-β1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology 2000; 118: 507-514.
106. 2 receptor, CRTH2. J Immunol 2002; 168: 981-985.
107. Marotta A, Tan C, Gray V, et al. Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene 2001; 20: 6250-6257.
108. Marx J. Anti-inflammatories inhibit cancer growth - but how?. Science 2001; 291: 581-582.
109. Hucker HB, Zacchei AG, Cox SV, et al. Studies on the absorption, distribution and excretion of indomethacin in various species. J Pharmacol Exp Ther 1966; 153: 237-249.
110. Kwan KC, Breault GO, Umbenhauer ER, et al. Kinetics of indomethacin absorption, elimination and enterohepatic circulation in man. J Pharmacokinet Biopharm 1976; 4: 255-280.
111. Williams CS, Watson AJM, Sheng H, et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045-6051.
112. Bamba H, Ota S, Kato A, et al. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 1999; 83: 470-475.
113. Hardwick JC, van der Brink GR, Offerhaus GJ, et al. NF-κB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 2001; 20: 819-827.
114. Williams CS, Tsujii M, Reese J, et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-1594.
115. Δ716 mouse intestinal polyps. Cancer Res 2002; 62: 506-511.
116. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily. Proc Natl Acad Sci USA 1997; 94: 11514-11519.
117. Djordjevic B, Lange CS, Schwartz MS, Rotman M. Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids. Acta Oncol 1998; 37: 735-739.
118. Matsushita R, Hattori K, Hayashi K, et al. Synergistic effect of indomethacin and bleomycin on tumor growth produced by activating immunity. Pharm Res 2001; 18: 243-245.
119. Hattori K, Matsushita R, Kimura K, et al. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. Biol Pharm Bull 2001; 24: 1214-1217.
120. Henry D, Lim LL-Y, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br Med J 1996; 312: 1563-1566.
121. Mizoguchi H, Hase S, Tanaka A, Takeuchi K. Lack of small intestinal ulcerogenicity of nitric oxide-releasing indomethacin, NCX-530, in rats. Aliment Pharmacol Ther 2001; 15: 257-267.
122. Williams JL, Borgo S, Hasan I, et al. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: iplications for colon cancer chemoprevention. Cancer Res 2001; 61: 3285-3289.
123. Bak AW, McKnight W, Li P, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998; 62: 367-373.